Xbrane Biopharma AB
STO:XBRANE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Xbrane Biopharma AB
Total Receivables
Xbrane Biopharma AB
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Xbrane Biopharma AB
STO:XBRANE
|
Total Receivables
kr12.3m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
10%
|
|
|
Biogaia AB
STO:BIOG B
|
Total Receivables
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Total Receivables
kr223.8m
|
CAGR 3-Years
47%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Total Receivables
kr796m
|
CAGR 3-Years
14%
|
CAGR 5-Years
29%
|
CAGR 10-Years
23%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Total Receivables
kr7.9B
|
CAGR 3-Years
11%
|
CAGR 5-Years
13%
|
CAGR 10-Years
31%
|
|
|
BioArctic AB
STO:BIOA B
|
Total Receivables
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Xbrane Biopharma AB
Glance View
Xbrane Biopharma AB is a biopharmaceutical company, which engages in the development and manufacture of biosimilars. The company is headquartered in Solna, Stockholm. The company went IPO on 2016-02-03. The company develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The firm's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.
See Also
What is Xbrane Biopharma AB's Total Receivables?
Total Receivables
12.3m
SEK
Based on the financial report for Dec 31, 2025, Xbrane Biopharma AB's Total Receivables amounts to 12.3m SEK.
What is Xbrane Biopharma AB's Total Receivables growth rate?
Total Receivables CAGR 10Y
10%
Over the last year, the Total Receivables growth was -64%. The average annual Total Receivables growth rates for Xbrane Biopharma AB have been -36% over the past three years , -27% over the past five years , and 10% over the past ten years .
